Product Detailed Description

liposomal Berberine Hydrochloride 70% — High Bioavailability Metabolic Support Supplement

Product Overview

Liposomal Berberine Hydrochloride 70% is a premium-grade dietary supplement ingredient delivering Berberine hydrochloride in an advanced liposomal delivery system. Berberine is a naturally occurring benzylisoquinoline alkaloid found in the stems, roots, and rhizomes of various medicinal plants, including Berberis aristata, B. darwinii, B. petiolaris, B. vulgaris, and Coptis chinensis. In its extracted form, berberine has been widely used in traditional Chinese and Ayurvedic medicine.

Berberine is a plant-derived quaternary isoquinoline alkaloid with a low water solubility. It exhibits broad therapeutic potential, including benefits related to metabolic health (e.g., hyperglycemia, lipid regulation, blood pressure, body composition, and polycystic ovary syndrome), modulation of gut microbiota, anti-inflammatory and antioxidant effects, and neuroprotective properties. However, its therapeutic use has been compromised by its hydrophobic characteristics, low stability, and poor bioavailability.

Why Liposomal Technology?

Berberine presents fundamental bioavailability challenges. The very low oral bioavailability of berberine (below 1%) makes its pharmacological effects hardly available and gives a serious limitation to its clinical utilization. This is attributed to its poor aqueous solubility, limited intestinal absorption, rapid metabolism, and rapid clearance from the bloodstream.

Liposomal encapsulation provides three critical advantages:

1. Digestive Protection — The phospholipid bilayer shields berberine from gastric acid degradation and premature metabolism during digestive transit, preserving its intact molecular structure until reaching optimal absorption sites in the small intestine. The FIL-BBR formulation demonstrated enhanced stability in simulated gastric fluid (SGF) in addition to a more sustained release in simulated intestinal fluid (SIF).

2. Enhanced Cellular Uptake — liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery and bypassing passive diffusion limitations. The optimized FIL-BBR formulation showed a sustained release of berberine at 59.03% compared to the unformulated control (46.73%) after 8 hours of dialysis.

3. Clinically Validated Superior Absorption — A randomized, double-blind, crossover pilot study in six healthy males demonstrated that liposomal berberine produced significantly higher pharmacokinetic responses compared with unformulated berberine, including a 70.1% increase in Cmax (p = 0.03) and a 42.8% increase in AUC₀–₂₄ (p = 0.03). No significant differences were observed between conditions in 24-hour changes in metabolic or safety markers, confirming that liposomal delivery substantially enhances berberine absorption without negatively affecting metabolic or safety parameters.

A separate in vivo bioavailability study using male Wistar rats demonstrated that the FIL-BBR formulation achieved a 3.37-fold higher relative oral bioavailability compared to unformulated berberine. The AUC₀–ₜ for BBR in FIL-BBR was 1.38 ng·h/mL, significantly greater than the unformulated BBR (0.41 ng·h/mL), and the Cmax for BBR in FIL-BBR (50.98 ng/mL) was far greater than unformulated BBR (15.54 ng/mL).

Product Specifications

Key Features

• High Purity — Standardized to ≥70% berberine hydrochloride by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Sunflower phospholipid bilayer encapsulation protects berberine from gastric degradation and enhances intestinal absorption, achieving 70.1% higher Cmax and 42.8% higher AUC₀–₂₄ versus unformulated berberine in human clinical study.

• AMPK Activation — Berberine strongly promotes the phosphorylation of AMPK and p38 MAPK, stimulating glucose uptake through the AMP-AMPK-p38 MAPK pathway and bypassing insulin signaling pathways.

• Glucose Metabolism Support — Berberine has demonstrated glucose-lowering effects in clinical trials, with most studies using 500 mg two to three times daily (1,000–1,500 mg total) for durations of 4–24 weeks.

• Lipid Regulation — Subgroup analysis from meta-analyses reveals that higher doses (≥750 mg/day) administered for longer durations (>8 weeks) produced greater reductions in total cholesterol, LDL-C, and triglycerides.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies and commercial products commonly recommend 300–1,500 mg of berberine hydrochloride per day. The standard dose used in clinical trials is 500 mg two to three times daily, totaling 1,000–1,500 mg per day. This dosing schedule is based on berberine‘s relatively short half-life of approximately 5–6 hours. A recent review of 46 clinical trials found that berberine is most commonly used at doses ranging from 500 mg to 1,500 mg/day, typically divided into 2–3 daily doses, for durations of 4 to 24 weeks. Subgroup analysis reveals that higher doses (≥750 mg/day) administered for longer durations (>8 weeks) produced greater reductions in total cholesterol, LDL-C, and triglycerides. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.